Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide to improve nutritional recovery after esophageal or gastric cancer surgery (OTIS)
2022-502745-98-00Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of octreotide in esophageal cancer and gastric cancer (GC) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Percent weight loss from baseline after surgery. Started Nov 2020; status: completed.
02
Drugs
octreotide
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on 2022-502745-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502745-98-00.